Nutrition Impact on PRGF Treatment for Tendinopathy

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorI.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

About this trial

Given the close correlation reported in the literature between onset and progression of tendon pathology in subjects affected by the alteration of metabolic disorders such as obesity, diabetes mellitus and lipidic metabolic alterations, with the present study the association between the nutritional state, metabolic profile and clinical outcome of patients following treatment with blood-derived orthobiological for shoulder tendinopathies will be evaluated.

The primary aim of this study is to identify the proportion of tendinopatic patients responsive and non-responsive to treatment with "Platelet rich growth factors" PRGF at six months follow up and the correlation with their nutritional status.

Eligibility criteria

Qualifiers

Male and female

Age ≥18 years and ≤ 70 years

Patients presenting shoulder tendinopathy

Signing of the Informed Consent of the Regain observational study

Disqualifiers

Pregnancy (ascertained by self-declaration), breastfeeding

Inability to follow the study protocol

Heart, kidney, oncological disease

Neuropsychiatric disease

Trial design

Treatments tested in this trial

  • Platelet rich growth factor injection (autologous product)

Treatment groups

52 Participants
are divided into 2 treatment groups